World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   136 records for 62 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7
Recruitment statusMain ID Public TitleDate of Registration
RecruitingNCT02189538
Effect of n-3 PUFA From Fish in Enteral Nutrition of Major Burn Patients
03/07/2014
Not recruitingNCT02132897
Fed Bioequivalence Study of CBZ Formulations
06/05/2014
RecruitingNCT02011334
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
04/12/2013
RecruitingNCT01966471
A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-004902-82-GBA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.21/11/2013
AuthorisedEUCTR2012-004902-82-ITA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.18/11/2013
AuthorisedEUCTR2012-004902-82-ESA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.05/12/2013
AuthorisedEUCTR2012-004902-82-BEA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.18/12/2013
AuthorisedEUCTR2012-004902-82-PLA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.23/04/2014
AuthorisedEUCTR2012-004902-82-CZA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.25/11/2013
AuthorisedEUCTR2012-004902-82-HUA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.22/11/2013
AuthorisedEUCTR2012-004902-82-SEA Study of trastuzumab emtansine Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer.23/12/2013
RecruitingJPRN-JapicCTI-142421Phase III clinical trial of trastuzumab emtansine and pertuzumab in patients with early breast cancer05/09/2014
17/10/2013
RecruitingNCT01970189
The International ITP Registry
19/09/2013
AuthorisedEUCTR2013-000087-29-IT
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000087-29-FIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/07/2013
AuthorisedEUCTR2013-000087-29-SIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.03/09/2013
AuthorisedEUCTR2013-000087-29-LVInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.02/09/2013
AuthorisedEUCTR2013-000087-29-EEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.10/10/2013
AuthorisedEUCTR2013-000087-29-GRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.21/10/2013
AuthorisedEUCTR2013-000087-29-ESInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.12/07/2013
AuthorisedEUCTR2013-000087-29-SEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.29/10/2013
AuthorisedEUCTR2013-000087-29-DEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.08/07/2013
AuthorisedEUCTR2013-000087-29-LTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.28/01/2014
AuthorisedEUCTR2013-000087-29-PLInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.04/11/2013
AuthorisedEUCTR2013-000087-29-BEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.13/01/2014
AuthorisedEUCTR2013-000087-29-PTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/09/2013
RecruitingNCT01905943A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia19/07/2013
02/07/2013
AuthorisedEUCTR2012-003138-17-AT
A comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003138-17-PTClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer04/06/2013
AuthorisedEUCTR2012-003138-17-GRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer25/06/2013
Not RecruitingEUCTR2012-003138-17-FIClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer20/05/2013
AuthorisedEUCTR2012-003138-17-ESClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer16/05/2013
AuthorisedEUCTR2012-003138-17-ITClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
AuthorisedEUCTR2012-003138-17-BGA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/06/2013
AuthorisedEUCTR2012-003138-17-GBA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
AuthorisedEUCTR2012-003138-17-SEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer30/05/2013
AuthorisedEUCTR2012-003138-17-LVA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/05/2013
AuthorisedEUCTR2012-003138-17-EEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
AuthorisedEUCTR2012-003138-17-IEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer.03/05/2013
AuthorisedEUCTR2012-003138-17-LTA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer26/04/2013
RecruitingNCT01860638A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma21/05/2013
24/04/2013
RecruitingNCT01800006
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region
25/02/2013
Not recruitingNCT01750749
Cell Therapy for Venous Leg Ulcers Pilot Study
13/12/2012
Not recruitingNCT01760356
Clinical Study of the Pharmacogenetic / Pharmacokinetic / Pharmacodynamic Relationships of Calcineurin Inhibitors Cyclosporine and Tacrolimus in Liver Transplant Recipients
01/12/2012
    
1 2 3 4 5 6 7
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history